Home › Migraine › NCT07616128
Study of EVO756 in Adults With Migraine
RecruitingPhase 2
A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults
Who can join
Ages 18 to 64 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders * Use of certain medications * Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
About the study
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
What is being tested
- EVO756, Dose 1 (drug)
- EVO756, Dose 2 (drug)
- Placebo (drug)
Sponsor: Evommune, Inc. · Participants: 330 · Started: Jul 29, 2026
Contact the study team
- Nichole Baio · Phone: (650) 319-4553
Official record on ClinicalTrials.gov — NCT07616128
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.